文献速递精神分裂症与精神病性障碍

首发精神病患者血清神经元细胞表面抗体的患病率与临床特征:病例对照研究

Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study.
PubMed 文献 · Lancet Psychiatry · 2016-12-08

该病例对照研究纳入228例首发精神病患者和105名健康对照,检测血清抗NMDAR、LGI1、CASPR2、GABAA受体和AMPA受体抗体。20例(9%)患者至少一种抗体阳性,对照组4例(4%),校正后差异无统计学意义;抗体阳性与阴性患者临床特征及6个月结局无差异。

要点

  • 首发精神病患者中9%存在神经元细胞表面抗体,NMDAR抗体占3%。
  • 抗体阳性与阴性患者PANSS、ACE-III、GAF及6个月结局无显著差异。
  • 研究提示需筛查所有首发精神病患者以检出潜在致病抗体。

核心结论

  • 部分首发精神病患者存在可能与疾病相关的NMDAR抗体,但其临床特征与无抗体患者无差异。
  • 仅筛查所有首发精神病患者才能检出这些潜在致病抗体。

研究设计与样本

  • 病例对照研究,招募英国35个精神卫生服务站点中14-35岁、抗精神病药治疗不足6周且至少一项PANSS条目≥4分的首发精神病患者228例,以及来自剑桥另一研究的健康对照105名。
  • 基线与6个月时完成PANSS、ACE-III、GAF评估,采用活细胞法检测血清抗NMDAR、LGI1、CASPR2、GABAA受体和AMPA受体抗体。

主要发现

  • 抗体阳性患者PANSS阳性分、PANSS总分和紧张症评分低于抗体阴性患者;其他PANSS条目、ACE-III及GAF基线评分相当,6个月结局无差异。

临床怎么用

  • 对首发精神病患者可考虑筛查神经元细胞表面抗体,尤其是NMDAR抗体,以识别潜在致病抗体携带者。
  • 抗体阳性与阴性患者临床特征重叠,不能仅凭症状特征判断是否需检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psychosis is a common presenting feature in antibody-mediated encephalitis, for which prompt recognition and treatment usually leads to remission. We aimed to investigate whether people with circumscribed schizophrenia-like illnesses have such antibodies-especially antibodies against the N-methyl-D-aspartate receptor (NMDAR)-more commonly than do healthy controls. METHODS: We recruited patients aged 14-35 years presenting to any of 35 mental health services sites across England with first-episode psychosis, less than 6 weeks of treatment with antipsychotic medication, and a score of 4 or more on at least one selected Positive and Negative Syndrome Scale (PANSS) item. Patients and controls provided venous blood samples. We completed standardised symptom rating scales (PANSS, ACE-III, GAF) at baseline, and tested serum samples for antibodies against NMDAR, LGI1, CASPR2, the GABAA receptor, and the AMPA receptor using live cell-based assays. Treating clinicians assessed outcomes of ICD diagnosis and functioning (GAF) at 6 months. We included healthy controls from the general population, recruited as part of another study in Cambridge, UK. FINDINGS: Between Feb 1, 2013, and Aug 31, 2014, we enrolled 228 patients with first-episode psychosis and 105 healthy controls. 20 (9%) of 228 patients had serum antibodies against one or more of the neuronal cell surface antibodies compared with four (4%) of 105 controls (unadjusted odds ratio 2·4, 95% CI 0·8-7·3). These associations remained non-significant when adjusted for current cigarette smoking, alcohol consumption, and illicit drug use. Seven (3%) patients had NMDAR antibodies compared with no controls (p=0·0204). The other antibodies did not differ between groups. Antibody-positive patients had lower PANSS positive, PANSS total, and catatonia scores than did antibody-negative patients. Patients had comparable scores on other PANSS items, ACE-III, and GAF at baseline, with no difference in outcomes at 6 months. INTERPRETATION: Some patients with first-episode psychosis had antibodies against NMDAR that might be relevant to their illness, but did not differ from patients without NMDAR antibodies in clinical characteristics. Our study suggests that the only way to detect patients with these potentially pathogenic antibodies is to screen all patients with first-episode psychosis at first presentation. FUNDING: Medical Research Council.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Lennox BR, Palmer-Cooper EC, Pollak T, et al. Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study. Lancet Psychiatry. 2016. PMID: 27965002. doi:10.1016/S2215-0366(16)30375-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。